← All trials
NCT01593254
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2012
- Primary completion
- Jan 30, 2022
- Completion date
- Feb 17, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Bristol-Myers SquibbLead sponsor
- PPDCollaborator
- Bristol-Myers SquibbStudy director
- MultiPharmaCollaborator
- ICONCollaborator
- Q2 solutionsCollaborator
- OBiS, IncCollaborator
- University of California, Los AngelesCollaborator
- University of Texas at HoustonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.